6533b859fe1ef96bd12b80ce
RESEARCH PRODUCT
Fibrinogen and von Willebrand factor in type II diabetes mellitus
Giuseppe MontaltoAlberto NotarbartoloAnna CalàG. MarinoFrancesco GennaroGiovanni DavìA. GanciI. CatalanoCarlo Giammarresisubject
medicine.medical_specialtybiologybusiness.industryEndocrinology Diabetes and MetabolismGeneral MedicineFibrinogenmedicine.diseaseAdenosine diphosphatechemistry.chemical_compoundEndocrinologyEndocrinologychemistryVon Willebrand factorInternal medicineMetabolic control analysisDiabetes mellitusInternal Medicinebiology.proteinMedicinePlateletRisk factorbusinessmedicine.drugMacrovascular diseasedescription
A hypercoagulable state may contribute to the formation of early vascular lesions in diabetes. The von Willebrand factor is required for the attachment of platelets to the subendothelium; fibrinogen is required for platelet aggregation. This study was designed to assess in type II diabetic patients plasma levels of fibrinogen and von Willebrand factor to see if these variables are associated with platelet aggregation responses to adenosine diphosphate (ADP). Fibrinogen and the von Willebrand factor were significantly increased in diabetics but only fibrinogen was significantly related to platelet aggregation for ADP. Strict metabolic control does not reduce the increased concentrations of these two proteins. Hyperfibrinogenaemia was related to the presence of macrovascular disease. Therefore measurements of plasma fibrinogen could be added to the cardiovascular risk factor profile of diabetic patients. Intervention studies are also needed to reduce the increased incidence of thrombotic diseases in patients with diabetes mellitus.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1992-01-01 | Acta Diabetologica |